Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report

A. Cuneo; L. Scarfò; G. Reda; M. Varettoni; F.M. Quaglia; M. Marchetti; L. De Paoli; F. Re; D. Pietrasanta; G.M. Rigolin; L. Orsucci; A. Ibatici; V. Gattei; F.R. Mauro; L. Trentin; L. Laurenti; R. Marasca; R. Foà; I. Angeletti; F. Chiurazzi; G. Del Poeta; M. Rosaria De Paolis; L. Farina; A. Ferrari; M. Gentile; D. Gottardi; A. Gozzetti; M. Leone; L. Levato; M. Maccaferri; L. Malerba; M. Motta; R. Murru; L. Nocilli; J. Olivieri; V. Stefoni; Campus CLL working group

doi:10.1182/BLOOD.2020006854

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report

A. Cuneo, L. Scarfò, G. Reda, M. Varettoni, F.M. Quaglia, M. Marchetti, L. De Paoli, F. Re, D. Pietrasanta, G.M. Rigolin, L. Orsucci, A. Ibatici, V. Gattei, F.R. Mauro, L. Trentin, L. Laurenti, R. Marasca, R. Foà, I. Angeletti, F. ChiurazziG. Del Poeta, M. Rosaria De Paolis, L. Farina, A. Ferrari, M. Gentile, D. Gottardi, A. Gozzetti, M. Leone, L. Levato, M. Maccaferri, L. Malerba, M. Motta, R. Murru, L. Nocilli, J. Olivieri, V. Stefoni, Campus CLL working group

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	763-766
Number of pages	4
Journal	Blood
Volume	136
Issue number	6
DOIs	https://doi.org/10.1182/BLOOD.2020006854
Publication status	Published - 2020

Keywords

ibrutinib
immunosuppressive agent
cancer incidence
cancer therapy
chronic lymphatic leukemia
coronavirus disease 2019
human
immunosuppressive treatment
Italy
Letter
manual ventilation
mortality
pandemic
Philadelphia chromosome positive cell
prevalence
priority journal
questionnaire
throat culture
Waldenstroem macroglobulinemia
aged
Betacoronavirus
complication
Coronavirus infection
disease management
isolation and purification
middle aged
very elderly
virus pneumonia
Aged
Aged, 80 and over
Coronavirus Infections
Disease Management
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Middle Aged
Pandemics
Pneumonia, Viral

Access to Document

10.1182/BLOOD.2020006854

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087666190&doi=10.1182%2fBLOOD.2020006854&partnerID=40&md5=6ee3c73b0ad6c9aac04ad462594720bf

Cite this

Cuneo, A., Scarfò, L., Reda, G., Varettoni, M., Quaglia, F. M., Marchetti, M., De Paoli, L., Re, F., Pietrasanta, D., Rigolin, G. M., Orsucci, L., Ibatici, A., Gattei, V., Mauro, F. R., Trentin, L., Laurenti, L., Marasca, R., Foà, R., Angeletti, I., ... group, C. CLL. W. (2020). Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report. Blood, 136(6), 763-766. https://doi.org/10.1182/BLOOD.2020006854

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report. / Cuneo, A.; Scarfò, L.; Reda, G.; Varettoni, M.; Quaglia, F.M.; Marchetti, M.; De Paoli, L.; Re, F.; Pietrasanta, D.; Rigolin, G.M.; Orsucci, L.; Ibatici, A.; Gattei, V.; Mauro, F.R.; Trentin, L.; Laurenti, L.; Marasca, R.; Foà, R.; Angeletti, I.; Chiurazzi, F.; Del Poeta, G.; Rosaria De Paolis, M.; Farina, L.; Ferrari, A.; Gentile, M.; Gottardi, D.; Gozzetti, A.; Leone, M.; Levato, L.; Maccaferri, M.; Malerba, L.; Motta, M.; Murru, R.; Nocilli, L.; Olivieri, J.; Stefoni, V.; group, Campus CLL working.

In: Blood, Vol. 136, No. 6, 2020, p. 763-766.

Research output: Contribution to journal › Article › peer-review

Cuneo, A, Scarfò, L, Reda, G , Varettoni, M, Quaglia, FM, Marchetti, M, De Paoli, L, Re, F, Pietrasanta, D, Rigolin, GM, Orsucci, L, Ibatici, A , Gattei, V, Mauro, FR, Trentin, L, Laurenti, L, Marasca, R, Foà, R, Angeletti, I, Chiurazzi, F, Del Poeta, G, Rosaria De Paolis, M, Farina, L , Ferrari, A, Gentile, M, Gottardi, D, Gozzetti, A, Leone, M, Levato, L, Maccaferri, M, Malerba, L, Motta, M, Murru, R, Nocilli, L, Olivieri, J, Stefoni, V & group, CCLLW 2020, 'Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report', Blood, vol. 136, no. 6, pp. 763-766. https://doi.org/10.1182/BLOOD.2020006854

Cuneo, A. ; Scarfò, L. ; Reda, G. ; Varettoni, M. ; Quaglia, F.M. ; Marchetti, M. ; De Paoli, L. ; Re, F. ; Pietrasanta, D. ; Rigolin, G.M. ; Orsucci, L. ; Ibatici, A. ; Gattei, V. ; Mauro, F.R. ; Trentin, L. ; Laurenti, L. ; Marasca, R. ; Foà, R. ; Angeletti, I. ; Chiurazzi, F. ; Del Poeta, G. ; Rosaria De Paolis, M. ; Farina, L. ; Ferrari, A. ; Gentile, M. ; Gottardi, D. ; Gozzetti, A. ; Leone, M. ; Levato, L. ; Maccaferri, M. ; Malerba, L. ; Motta, M. ; Murru, R. ; Nocilli, L. ; Olivieri, J. ; Stefoni, V. ; group, Campus CLL working. / Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report. In: Blood. 2020 ; Vol. 136, No. 6. pp. 763-766.

@article{36da7c2bac314c07a94c992b9f663609,

title = "Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report",

keywords = "ibrutinib, immunosuppressive agent, cancer incidence, cancer therapy, chronic lymphatic leukemia, coronavirus disease 2019, human, immunosuppressive treatment, Italy, Letter, manual ventilation, mortality, pandemic, Philadelphia chromosome positive cell, prevalence, priority journal, questionnaire, throat culture, Waldenstroem macroglobulinemia, aged, Betacoronavirus, complication, Coronavirus infection, disease management, isolation and purification, middle aged, very elderly, virus pneumonia, Aged, Aged, 80 and over, Coronavirus Infections, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Pandemics, Pneumonia, Viral",

author = "A. Cuneo and L. Scarf{\`o} and G. Reda and M. Varettoni and F.M. Quaglia and M. Marchetti and {De Paoli}, L. and F. Re and D. Pietrasanta and G.M. Rigolin and L. Orsucci and A. Ibatici and V. Gattei and F.R. Mauro and L. Trentin and L. Laurenti and R. Marasca and R. Fo{\`a} and I. Angeletti and F. Chiurazzi and {Del Poeta}, G. and {Rosaria De Paolis}, M. and L. Farina and A. Ferrari and M. Gentile and D. Gottardi and A. Gozzetti and M. Leone and L. Levato and M. Maccaferri and L. Malerba and M. Motta and R. Murru and L. Nocilli and J. Olivieri and V. Stefoni and group, {Campus CLL working}",

note = "Cited By :7 Export Date: 16 February 2021 CODEN: BLOOA Correspondence Address: Fo{\`a}, R.; Hematology, Via Benevento 6, Italy; email: rfoa@bce.uniroma1.it Chemicals/CAS: ibrutinib, 936563-96-1 Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, 21198 Funding text 1: This study was partly supported by Associazione Italiana Ricerca sul Cancro, Special 5x1000 Program Metastases (21198), Milan, Italy (R.F.), and BEAT Leukemia (A.C.). References: Fo{\`a}, R, Bonifacio, M, Chiaretti, S, Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study (2020) Br J Haematol, 190 (1), pp. e3-e5; Li, W, Wang, D, Guo, J, COVID-19 in persons with chronic myeloid leukaemia [published online ahead of print 18 May 2020] Leukemia; Breccia, M, Abruzzese, E, Bocchia, M, Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy Leukemia, , A Campus CML survey [published online ahead of print 18 June 2020]; Hallek, M., Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment (2019) Am J Hematol, 94 (11), pp. 1266-1287; Wierda, WG, Byrd, JC, Abramson, JS, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology (2020) J Natl Compr Canc Netw, 18 (2), pp. 185-217; Treon, SP, Castillo, JJ, Skarbnik, AP, The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients (2020) Blood, 135 (21), pp. 1912-1915",

year = "2020",

doi = "10.1182/BLOOD.2020006854",

language = "English",

volume = "136",

pages = "763--766",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "6",

}

TY - JOUR

T1 - Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report

AU - Cuneo, A.

AU - Scarfò, L.

AU - Reda, G.

AU - Varettoni, M.

AU - Quaglia, F.M.

AU - Marchetti, M.

AU - De Paoli, L.

AU - Re, F.

AU - Pietrasanta, D.

AU - Rigolin, G.M.

AU - Orsucci, L.

AU - Ibatici, A.

AU - Gattei, V.

AU - Mauro, F.R.

AU - Trentin, L.

AU - Laurenti, L.

AU - Marasca, R.

AU - Foà, R.

AU - Angeletti, I.

AU - Chiurazzi, F.

AU - Del Poeta, G.

AU - Rosaria De Paolis, M.

AU - Farina, L.

AU - Ferrari, A.

AU - Gentile, M.

AU - Gottardi, D.

AU - Gozzetti, A.

AU - Leone, M.

AU - Levato, L.

AU - Maccaferri, M.

AU - Malerba, L.

AU - Motta, M.

AU - Murru, R.

AU - Nocilli, L.

AU - Olivieri, J.

AU - Stefoni, V.

AU - group, Campus CLL working

N1 - Cited By :7 Export Date: 16 February 2021 CODEN: BLOOA Correspondence Address: Foà, R.; Hematology, Via Benevento 6, Italy; email: rfoa@bce.uniroma1.it Chemicals/CAS: ibrutinib, 936563-96-1 Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, 21198 Funding text 1: This study was partly supported by Associazione Italiana Ricerca sul Cancro, Special 5x1000 Program Metastases (21198), Milan, Italy (R.F.), and BEAT Leukemia (A.C.). References: Foà, R, Bonifacio, M, Chiaretti, S, Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study (2020) Br J Haematol, 190 (1), pp. e3-e5; Li, W, Wang, D, Guo, J, COVID-19 in persons with chronic myeloid leukaemia [published online ahead of print 18 May 2020] Leukemia; Breccia, M, Abruzzese, E, Bocchia, M, Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy Leukemia, , A Campus CML survey [published online ahead of print 18 June 2020]; Hallek, M., Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment (2019) Am J Hematol, 94 (11), pp. 1266-1287; Wierda, WG, Byrd, JC, Abramson, JS, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology (2020) J Natl Compr Canc Netw, 18 (2), pp. 185-217; Treon, SP, Castillo, JJ, Skarbnik, AP, The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients (2020) Blood, 135 (21), pp. 1912-1915

PY - 2020

Y1 - 2020

KW - ibrutinib

KW - immunosuppressive agent

KW - cancer incidence

KW - cancer therapy

KW - chronic lymphatic leukemia

KW - coronavirus disease 2019

KW - human

KW - immunosuppressive treatment

KW - Italy

KW - Letter

KW - manual ventilation

KW - mortality

KW - pandemic

KW - Philadelphia chromosome positive cell

KW - prevalence

KW - priority journal

KW - questionnaire

KW - throat culture

KW - Waldenstroem macroglobulinemia

KW - aged

KW - Betacoronavirus

KW - complication

KW - Coronavirus infection

KW - disease management

KW - isolation and purification

KW - middle aged

KW - very elderly

KW - virus pneumonia

KW - Aged

KW - Aged, 80 and over

KW - Coronavirus Infections

KW - Disease Management

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Middle Aged

KW - Pandemics

KW - Pneumonia, Viral

U2 - 10.1182/BLOOD.2020006854

DO - 10.1182/BLOOD.2020006854

M3 - Article

VL - 136

SP - 763

EP - 766

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -